A Phase 1 / 2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

Grant

Date/time Interval

  • December 8, 2014 - December 7, 2016
  • Total Award Amount

  • 8200.00
  • Direct Costs

  • 6508.00
  • Sponsor Award Id

  • Contributor

  • Ana Galtarossa Xavier   Investigator